fbpx

Day

December 11, 2015
Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Dr. William J. Polvino steps down as President and CEO after more than six years in the role.
93% of patients had full or partial cyst resolution at 12 months. No post-operative infections reported during follow-up period. No fractures reported during the follow-up period

News

Experienced neuroscientist at the helm of The Brain Prize
30. June 2020
Eight promising young researchers receive Lundbeck Foundation Fellowships
16. June 2020
Denmark Gets Its First Master’s Degree Programme in Neuroscience
4. June 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge